EU H2020
Funding Opportunities for Health
10th October 2016
Objectives:

- Inform you about EU funding opportunities coming up in 2017
- Support organisations looking at developing proposals
- Support consortium building

Agenda

<table>
<thead>
<tr>
<th></th>
<th>Introduction</th>
<th>Gabriela Martinez, KTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>H2020 Funding Opportunities 2017</td>
<td>Giorgio Clarotti, EC</td>
</tr>
<tr>
<td>3</td>
<td>How to put a good proposal together</td>
<td>Sandeep Sandhu, MRC</td>
</tr>
<tr>
<td>4</td>
<td>Support organisations</td>
<td>Sandeep Sandhu, MRC</td>
</tr>
<tr>
<td>5</td>
<td>Q&amp;A consortium building opportunities</td>
<td>All</td>
</tr>
</tbody>
</table>

Please type your questions in the question pane.
UK Government guarantees EU funding beyond date UK leaves the EU

The UK Government and the European Commission confirmed earlier in the summer that the UK EU referendum result had no immediate effect on UK organisations applying to or participating in Horizon 2020 and that they could continue to apply to the programme in the usual way.

Statement from Jo Johnson, MP:  https://www.gov.uk/government/news/statement-on-higher-education-and-research-following-the-eu-referendum

In addition, the HM Treasury (the UK finance ministry) guaranteed that all UK organisations bidding individually or as members of consortia for Horizon 2020 projects, while the UK is still a member of the EU, will have certainty over future funding with the Treasury underwriting the payments of such awards, even when specific projects continue beyond the UK’s departure from the EU.

EC statement on Participation of UK entities

• Before and during negotiations under Art. 50, the UK remains a full member of the European Union with all the rights and obligations in the Framework Programmes for Research and Innovation that derive from this.

• During this time a UK organisation will be treated like any other organisation from an EU Member State in a call for proposals or call for tender.

• What happens at the end of the negotiations under Art. 50 will depend on the agreements reached and can currently not be predicted.
The societal challenge
'Health, demographic change and well-being'
Work Programme 2017

UK Information Day webinar
10 October 2016

Giorgio Clarotti, PhD
DG Research and Innovation
Research and innovation – a growing priority for the EU
*Horizon 2020 supports Commission priorities*

- Jobs and growth
- Societal challenges
- European industrial leadership and competitiveness
- EU international excellence

• Couple research to innovation
• Provide evidence-base for addressing societal challenges, supporting EU policies and better regulation
• Strengthen research capacities and innovation strategies across all Member States
• Multidisciplinarity and synergies
• Address people's concerns
Ways to measure impact

Evidence based policy making
- Medicines for children
- Health Technology Assessment (HTA)
- ATMP
- and many others…

Taking the lead in new areas of growth
- Personalised medicine

Responding to emergencies
- EU Allocates $11Mln to Support Zika Virus Research

Knowledge creation and exploitation
- Jobs
- SME: SMALL & MEDIUM ENTERPRISES
Health Research in H2020

- **Excellent science €24bn***
- **Industrial leadership €17bn***
- **Future and Emerging Technologies**
- **Marie Skłodowska Curie**
- **Research Infrastructures**
- **SME instrument**
- **Industrial leadership €17bn***
- **Future and Emerging Technologies**
- **Marie Skłodowska Curie**
- **Research Infrastructures**
- **SME instrument**
- **Collaborative projects**
- **AAL-2**
- **EDCTP-2**
- **LEIT Biotech**
- **Eureka Eurostars-2**
- **Financial instruments**
- **SC1 Health €7.3bn (of €31bn)**

* Figure to be updated following EFSI investments in 2016-2017 and FP7 recovery in 2016
Health Research in H2020

- Collaborative R&I projects
- Public-Private Partnership with big Pharma
- Public-Public Partnerships with EU Member States & beyond
- Grants for small businesses
- InnovFin: Loans for small & large companies
- Education – R&D - Innovation
- Prizes
- Blue sky research
- More years, better lives
- HORIZON 2020 Marie Skłodowska-Curie actions
Various instruments along the value chain
IMI2:

- Covers the entire medical research and innovation value chain
- Strategic Research Agenda is based on the WHO Priority Medicine Report renewed in July 2013
- Involves pharmaceutical industries as well as others (diagnostics, imaging, animal health, ICT etc.)
- Supports World class research and innovation leading to breakthrough vaccines, medicines and treatments

EDCTP2:

- launched in December 2014
- almost €700 million EU co-funding, matching the same Member States contribution
- broader scope: including HIV, TB, malaria, neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation
- longer duration: 10 years
SC1 Work Programme 2017

in brief

Call 'Personalised Medicine'
11 topics

Including 'coordination activities'
4 topics

- SME Instrument
  2 topics (unchanged from 2016)

- Other Actions
  13 items (incl. InnovFin ID and Birth Day Prize)
Topics amended in SC1 WP 2017 calls

- **PM-07** (Promoting Mental Health): Reference to migrants
- **PM-20-2017**: Development of new methods & measures for improved economic evaluation + efficiency measures in health sector
- **SC1-HCO-07–2017**: Global Alliance for Chronic Diseases (GACD) – Topic on mental health developed
- **NEW HOA**: Support to the 'World RePORT', Tracking research outcomes
- **Additional budget**: 48 M€, +35 M€ to SMEs-5, +13 M€ to PM-02,-08,-10
Topics amended in SC1 WP 2017 calls

• **NEW SC1-HCO-17–2017**: CSA for Support for large scale uptake of Digital Innovation for Active and Healthy Ageing

• **PM-16, 17 and 19 -2017**: minor textual changes for further clarification

• **PM-15**: Personalised coaching for well-being and care of people as they age: budget increased by 1.5 M EUR to 26.5 M EUR
2nd European Summit on Digital Innovation for Active and Healthy Ageing
5-8 December 2016, Brussels

Day 1 _ 5th Dec. Global Conference on Innovation for AHA
Day 2 _ 6th Dec. Blueprint on Digital Transformation
Day 3 _ 7th Dec. Conference of Partners EIP on AHA
Day 4 _ 8th Dec. Partner Events

Details will soon be announced at http://ec.europa.eu/eip/ageing
Europe is a leader in personalised medicine

Personalised medicine drives innovation and contributes to sustainable healthcare by better prevention, prediction and disease management strategies

Personalised Medicine Conference 2016 has launched IC PerMed
European Human Biomonitoring Initiative

- **Launch Event of the European Human Biomonitoring Initiative**: 8 December 2016, Brussels, under the Slovakian Presidency of the Council of the EU

- Creating a European joint programme for monitoring and scientific assessment of human exposures to chemicals and potential health impacts – 26 countries and the European Commission, co-funded by Horizon 2020

- Coordinating HBM initiatives in Europe at national and EU level with special focus on a two way dialogue between policy and science in support of evidence based policy making

- **Main aim**: to coordinate and advance human biomonitoring in Europe and thereby provide better evidence of the actual exposure of citizens to chemicals to support policy making
Health Horizon Prizes

**Horizon Prize**

**Betten Use of Antibiotics**

*Can you crack the challenge?*

Scope: discover a rapid test to identify, at the point of care, patients with upper respiratory tract infections that can be treated safely without antibiotics.

Funding: €1 million

Submit your entry until 17 August 2016

Award ceremony: November 2016

---

'challenge' prizes offering a cash reward to whoever can most effectively meet a defined challenge

**Horizon Prize**

**Birth Day**

*Can you crack the challenge?*

Joint initiative between the European Commission and Bill & Melinda Gates Foundation (possible additional fundings with MSD for Mothers)

Funding: €2 million

Scope: a novel solution to improve the outcome of facility-based deliveries (of a clinical, technological or managerial nature, or a combination of these)

End date: 6 September 2017
Horizon 2020: more opportunities for SMEs

• **Integrated approach** – around 20% of the total budget for societal challenges and LEITs to go to SMEs

• **Simplification** of particular benefit to SMEs (e.g. single entry point)

• A **new SME instrument** will be used across all societal challenges as well as for the LEITs

• A dedicated activity for research-intensive SMEs in 'Innovation in SMEs'

• 'Access to risk finance' with a dedicated SME scheme (debt and equity facility)
SME instrument WP 2017

SMEInst-05 Supporting innovative SMEs in the healthcare biotechnology sector (RTD)
- 80 million EUR budget for 2017 (+45%)!
  a) 'cell technologies' – all remaining cut-off dates in 2016 for phase I and for phase II. **All cut-off dates in 2017 for phase II only.**
  b) 'validation of biomarkers and/or diagnostic medical devices' – **only phase II for the first cut-off date in 2017 only.**

SMEInst-06 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
Phase I and phase II for all remaining cut-off dates in 2016 and 2017
Timetable 2017 Work Programme

• **Amended work programme 2017:**
  
  *Adoption and opening of calls planned for **end July 2016***

• 2017 call deadlines: No amendments!
  
  ✓ RTD 2-stage: 04 October 2016 (first-stage), 11 April 2017 (second-stage)
  ✓ RTD single-stage: 11 April 2017
  ✓ CNECT (PM-15): 31 January 2017
  ✓ CNECT (PM-16, -17, -19): 14 March 2017

• Outlook to work programme 2018-2020... – Adoption planned for 4th quarter 2017
## Timetable for WP 2018-20

<table>
<thead>
<tr>
<th>Year</th>
<th>Next Work Programme</th>
</tr>
</thead>
</table>
| 2016 | - SC1 AG meetings (Q1/Q2) – AG report circulated on 8/6/2016  
- Stakeholder consultation (Q1/Q2) based on AG report – July 2016  
- Consultation Member States via PC + input on national research (Q2/Q3) – July 2016  
- Joint PC and AG meeting: 21-22 September 2016  
- Scoping papers and Strategic Programming documents (Q3)  
- Endorsement by Strategic Programming Committee (24 November) |
| 2017 | - Consultation PC configurations on WPs drafts (Q1-Q3)  
- Adoption on the WP 2018-20 (Q4) (should incorporate the results of the Horizon 2020 interim evaluation) |
| 2018 | - Adoption of financial decision for 2019 (Q2) |
| 2019 | - Adoption of financial decision for 2020 (Q2) |
SSH disciplines

sociology
psychology
anthropology
cultural studies
demography
education
religion

history
economics
administration
political science
philosophy
ethics
law
How to include / assess SSH

• Some specific SSH areas that might be considered for health research are: **ethics, vulnerability, inequality and legal matters**

• SSH needs to be initiated upstream, and not simply considered as an add-on => Help achieving impact through SSH

• Important to check: a) the level of interaction between STEM and SSH; b) the level of rigour of application of SSH c) and, in the scope, the areas that go beyond health economics

• Evaluators → look for evaluators who have a **broader knowledge** (economics, statistics, psychology, anthropology and behavioural science)

• Importance to **disseminate** more information on good practices in embedding SSH
SSH inclusion - Example (I)

SC1-PM-07-2017: Promoting mental health and well-being in the young

Scope: Proposals should develop population-oriented primary prevention interventions to interventions should build on but may go beyond existing state-of-the-art knowledge on biological, psychological and social determinants of mental well-being such as societal, cultural, work life, lifestyle, epidemiological, economic and environmental perspectives. The considered. The interventions should use a holistic approach, taking gender and health inequality aspects into account, in increasing resilience and empowering the young. The interventions to be developed should reflect the diversity of the different countries and regions in Europe and beyond. The research should pay particular attention to ethical issues. The

Expected Impact: Short or medium term impact, likely during the lifetime of the project:

- Improved mental well-being in the targeted group of young people.

- The innovative interventions will create a strong evidence base for mental well-being promotion programmes in Europe, contributing to greater health equity and improved societal benefits.

Longer term impact, likely beyond the lifetime of the project:

- Improved mental well-being in youth should contribute to reducing school and college/university dropout in the short term, strengthening personal confidence and cognitive function, improving educational efforts and enhancing employability.
SSH inclusion - Example (II)

SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population

Scope: Proposals should compare the use of currently available preventative or therapeutic (pharmacological as well as non-pharmacological) healthcare interventions in adults. While databases and meta-analyses may be considered for this topic. Where relevant the study population should address gender as well as socio-economic differentials in health and/or any other factors that affect health equity.
Sex and Gender interact
Regitz-Zagrosek, V. (2012). Sex and Gender Differences in Health. EMBO Reports, 13 (7): 596-603
What does gender dimension mean?

Integrating the **gender dimension** in research content means taking into account the biological characteristics of both females and males (sex) and the evolving social and cultural features of women and men, girls and boys (gender).

<table>
<thead>
<tr>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
</tr>
<tr>
<td>Refers to biological characteristics of women and men, boys and girls, in terms of reproductive organs and functions based on chromosomal complement and physiology. As such, sex is globally understood as the classification of living beings as male and female, and intersexed.</td>
</tr>
</tbody>
</table>
Gender inclusion – Examples

SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population

Scope: Proposals should compare the use of currently available preventative or therapeutic (pharmacological as well as non-pharmacological) healthcare interventions in adults. While databases and meta-analyses may be considered for this topic. Where relevant the study population should address gender as well as socio-economic differentials in health and/or any other factors that affect health equity.

SC1-PM-07-2017: Promoting mental health and well-being in the young

Scope: Proposals should develop population-oriented primary prevention interventions to promote mental well-being of young people and assess them for their effectiveness. [...] The interventions should use a holistic approach, taking gender and health inequality aspects into account, in increasing resilience and empowering the young.

SC1-PM-11-2016-2017: Clinical research on regenerative medicine

Scope: Proposals should target regenerative medicine therapies which are ready for clinical (in-patient) research and should focus on one specific clinical phase of work [...] Sex and gender differences should be investigated, where relevant.
Nanotechnologies, Advanced Materials, Biotechnology and Production (NMBP)

Nanomedicine


QUESTIONS?
• Ethics issues to be carefully considered in proposals
• Check on EU guiding principles
• Ethics evaluation of all proposals included in priority lists
• Ethics requirements to be implemented in funded projects
International cooperation
Global challenges call for global responses

- Engaging in international cooperation is essential to attract talent, access knowledge and markets, thus increasing EU competitiveness

- Horizon 2020 is a vehicle to work together with the best worldwide

International Cooperation Strategy
Enhancing and focusing EU international cooperation in research and innovation
Horizon 2020 – Open to the World

General opening
Horizon 2020 is fully open to participation of entities from across the globe

Targeted opening
Many topics are flagged as being specifically relevant for international cooperation, identifying upfront the targeted area and partner country or region
List of countries providing matching funds

Topic conditions and documents

Please read carefully all provisions below before the preparation of your application.

1. **List of countries and applicable rules for funding:** described in [part A of the General Annexes](#) of the General Work Programme.

   Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in some Horizon 2020 topics (to check funding conditions, follow the links to [Australia](#), [Canada](#), [China](#), [Hong Kong & Macau](#), [India](#), [Japan](#), [Republic of Korea](#), [Mexico](#), [Russia](#), [Taiwan](#), [USA](#)).

   *Note that US participants in projects under the Horizon 2020 "Health, Demographic Change and Wellbeing" Societal Challenge are automatically eligible for EU-funding according to the provisions in the relevant work programme*
Multi-lateral health research activities

IRDiRC
www.irdirc.org

InTBIR
http://intbir.nih.gov/

IHEC
http://ihec-epigenomes.org/

International Cancer Genome Consortium
https://icgc.org/

Global Genomic Medicine Collaborative
G2MC

Global Alliance for Chronic Diseases
www.gacd.org/

Global Research Collaboration for Infectious Disease Preparedness
http://www.gloid-pid-r.org/
SC1 and international cooperation

- Reference to specific multi-lateral initiatives
- Mutual opening of research programmes with Third Countries (USA)
- Funding of Third Countries entities by their own funding agencies for participating to Horizon 2020 (e.g. Australia, Korea, Switzerland)
- Specific actions (e.g. Brazil for ZIKA virus)
Communicating H2020 projects

*Increased importance of communication*

- Communication plan and work package in the proposal and the grant agreement (GA article 38.1)
- Inform EC/Agency in advance of communication activities expected to have a major media impact
- Promote your project and its results beyond the project's own community
- Communicate your research in a way that is understood by non-specialist, e.g. the media and the public

*Communication ≠ Dissemination*

- Dissemination (GA article 29) is a separate obligation (e.g. through scientific articles and conferences)
Good communication

✓ Start at the outset, continue through entire lifetime
✓ Plan strategically
✓ Identify and set clear communication objectives
✓ Target audiences beyond own community
✓ Choose pertinent messages
✓ Use the right medium and means
Guidance

- Horizon 2020 Annotated Grant Agreement
- Brochure "Communicating EU Research & Innovation - Guidance for project participants"

Fit for Health 2.0
Support to SMEs & Researchers in FP7 and Horizon 2020 health-oriented projects
Support for Applicants

Strategy development for SMEs

Fit for Health 2.0 Innovation Cycle

Implementing projects

Exploiting project results
Support for Applicants – finding project partners

International Fit for Health 2.0 database including a matchmaking facility
- Search in our pool of more than 1,600 expertise profiles
- Automatic matchmaking of projects and available profiles (based on keywords and text)

Helping to exploit your project results

Exploitation partnering day
- Focus on products / solutions to be exploited
- Bilateral meetings with potential partners from research business & finance

Next event: 15-17 November 2016, MEDICA, Duesseldorf, Germany
Particular Support for SMEs

Trainings on strategy development

- Writing and communicating the business plan
- Innovative Business Planning around Intellectual Property (IP)
- Principles of valuation & negotiation with equity investors in life sciences
- Case study: value a drug in development & negotiate a fair licensing deal
- Train the pitching!

Next training: 12-13 October 2016 in Vienna, Austria
Registration will open on 1 September 2016!

For any questions, please contact the coordinator:
ines.haberl@ffg.at
Thank you for your attention!
How to put a good proposal together
Proposal outline

One page proposal summary to help focus ideas and for consortium building

- **WHY** the project is being carried out
- **WHAT** is expected to be achieved…what is not expected to be achieved: **Objectives**
- **WHO** is going to do the work
- **HOW** the project is going to achieve the above
Proposal outline

- Tell a story: explain the benefit of your project idea
- Simple structure
- Balance of work between Partners and Work package leaders
- Don’t have too many deliverables
Writing the proposal

Refer to the evaluation criteria - there are three elements, each scored out of five:

- **Excellence** - credibility of the proposed approach, ambition of the work, innovation potential, is beyond the state of the art
- **Implementation** - how you will carry out the work and the quality of the consortium
- **Impact** - Strengthening the competitiveness and growth of companies, effectiveness of the project to exploit and disseminate the project results
Writing the proposal

- Write in plain English
- Respect the page limits
- Be concise
- Get impartial colleagues to read it before submission
General Guidance

- How will proposed work advance state-of-the-art?
- What makes the proposal "special"?
- Are disciplines, basic and applied aspects well connected?
- How can findings be best disseminated, tested, demonstrated and applied – in different European settings?
- How are users/stakeholders of research outputs involved in implementation of work?
NHS European Office

Who are we?
– Established 2007
– Part of the NHS Confederation
– Funded by national NHS bodies

How can the NHS European Office help NHS Organisations?

1. Information and briefings on EU funding programmes and intelligence on EU funding opportunities
2. Advice on finding the right partners from other European countries
3. Feedback on draft proposals
4. Linking your ideas and proposals with the EU policy agenda

sarah.collen@nhsconfed.org
Medical Research Council

Dedicated to improving human health through the best scientific research.

Its work, on behalf of the UK taxpayer, ranges from molecular level science to public health medicine and understanding of the human body in health and disease.

MRC's role in Horizon 2020

The MRC provides the National Contact Point for the Health, Demographic Change and Wellbeing Challenge.

The MRC also leads the UK delegation on the Horizon 2020 Programme Committee for the Health, Demographic Change and Wellbeing Challenge.

UK Contact: Dr Sandeep Sandhu – Horizon 2020 Health NCP
sandeep.sandhu@headoffice.mrc.ac.uk
Innovate UK is the UK’s innovation agency. It is an executive non-departmental public body, sponsored by the Department for Business, Energy & Industrial Strategy.

National Contact Points (NCPs) are publicly funded and offer an accessible, free and confidential service for all types of organisations interested participating in Horizon 2020.

The services include:
- Provide impartial advice on European funding, tailored to each individual organisation.
- Advice on administrative procedures and contractual issues
- Assistance on proposal writing
- Distribution of documentation (forms, guidelines, manuals etc.)

Each area of Horizon 2020 has a NCP who you can contact for more information and this support is repeated across Europe
https://www.h2020uk.org/national-contact-points

UK Contact: Jerome de Barros – Horizon 2020 Health NCP
jerome.debarros@innovateuk.gov.uk
KTN is the UK’s thematic innovation network (60K members). It brings together businesses, entrepreneurs, academics and funders to develop new products, processes and services.

- **Support UK based businesses in engaging with Europe and H2020**
- **Influence the Funding priorities within H2020**
  - Working with NCPs and the EEN within the UK to optimise support to UK companies.
  - **Building on links** with the European Commission, European Technology Platforms Innovate UK Brussels Office.
  - Participate in projects where they support the KTN purpose and strategy e.g. CSAs
  - Identifying opportunities for collaborations across industry sectors and along value chains.
  - Consortium building – using our networks to find the right UK partner.
  - **Provide sector specific advice** – KTN has deep industry knowledge across all sectors relevant to UK economy.

**Contact:** [gabriela.juarezmartinez@ktn-uk.org](mailto:gabriela.juarezmartinez@ktn-uk.org)
Enterprise Europe Network (EEN) is your Gateway to international business opportunities.

As the Worlds largest business support network, it brings together 600 partner organisations in more than 60 countries.

EEN offer a local route to free, tailored support and advice to help your business innovate and grow internationally, faster. EEN’s many services are there for you to:

- find the right partners for research & development and innovation
- develop and commercialise your ideas
- find new markets for your innovation and products
- access funding and finance
- improve your ability to innovate and grow internationally

To find out more Call: 0300 123 3066 or email contact@enterprise-europe.co.uk

Countries in which EEN operates http://een.ec.europa.eu/about/branches
Thank you

European Commission
NHS Confederation: sarah.collen@nhsconfed.org
MRC – NCP sandeep.sandhu@headoffice.mrc.ac.uk
Innovate UK – NCP jerome.debarros@innovateuk.gov.uk
EEN – UK contact@enterprise-europe.co.uk
KTN – Health gabriela.juarezmartinez@ktn-uk.org